Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study

Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor developed to treat anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open‐label, 24‐week study investigated the efficacy and safety of roxadustat in Japanese CKD patients with anemia on peritoneal di...

Descripción completa

Detalles Bibliográficos
Autores principales: Akizawa, Tadao, Otsuka, Tetsuro, Reusch, Michael, Ueno, Mai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079122/
https://www.ncbi.nlm.nih.gov/pubmed/31222951
http://dx.doi.org/10.1111/1744-9987.12888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079122/
https://www.ncbi.nlm.nih.gov/pubmed/31222951
http://dx.doi.org/10.1111/1744-9987.12888

Ejemplares similares